GHライブシグナル | Getagraph.comで利益を最大化

買う 94167 min ago

@ $22.28

発行日: 15 2月 2024 @ 03:20

リターン: -27.87%

前回のシグナル: 2月 14 - 23:30

前回のシグナル: 売る

リターン: 1.83 %

Live Chart Being Loaded With Signals

Commentary (20 4月 2024 @ 05:00):

Stats
本日の出来高	1.85M
平均出来高	2.00M
時価総額	1.96B
EPS	$0 ( 2024-02-22 )
次の収益日	( $-0.940 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.75
ATR14	$0.0280 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Tariq Musa	Sell	249	Restricted Stock Units
2024-04-15	Tariq Musa	Buy	249	Common Stock
2024-04-15	Saia John G.	Buy	7 569	Common Stock
2024-04-15	Saia John G.	Sell	2 701	Common Stock
2024-04-15	Saia John G.	Sell	1 108	Common Stock

INSIDER POWER
-46.43
Last 99 transactions
Buy: 864 284 \| Sell: 2 349 747

ボリューム相関

長: 0.47 (neutral)

短: 0.86 (strong)

Signal:(63.11) Same movement expected

Guardant Health Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Guardant Health Inc 相関 - 通貨/商品

-0.77
( moderate negative )

-0.75
( moderate negative )

0.00
( neutral )

-0.75
( moderate negative )

-0.23
( neutral )

0.28
( neutral )

Guardant Health Inc 財務諸表

Annual	2023
収益:	$563.95M
総利益:	$336.90M (59.74 %)
EPS:	$-4.28

Q4	2023
収益:	$155.05M
総利益:	$236.19M (152.33 %)
EPS:	$-1.580

Q3	2023
収益:	$143.03M
総利益:	$85.42M (59.72 %)
EPS:	$-0.730

Q2	2023
収益:	$137.15M
総利益:	$83.30M (60.74 %)
EPS:	$-0.670

Financial Reports:

No articles found.

Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.